Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Pharmsville Co. Ltd. (318010:KRX), powered by AI.
Pharmsville Co. Ltd. is currently trading at ₩3,560. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Pharmsville Co. Ltd. on Alpha Lenz.
Pharmsville Co. Ltd.'s P/E ratio is 9.8.
“Pharmsville Co. Ltd. trades at a P/E of 9.8 (undervalued) with modest ROE of 4.4%.”
Ask for details →Pharmsville Co. Ltd. is a pharmaceutical company dedicated to the research, development, manufacturing, and distribution of medical drugs and therapies. As an integral player in the healthcare sector, Pharmsville focuses on creating medications that address a wide range of medical needs, including chronic illnesses and rare diseases. The company's portfolio includes prescription drugs, over-the-counter products, and biotechnology solutions, catering to both healthcare professionals and consumers. Its research and development initiatives are fueled by state-of-the-art laboratories and collaborations with medical institutions, aiming to bring innovative and effective treatments to the market. Pharmsville Co. Ltd. plays a crucial role in the pharmaceutical industry by contributing to the advancement of medical science and enhancing patient care. Its operations significantly impact public health, influencing drug availability, accessibility, and affordability across various regions. With a commitment to quality and compliance, Pharmsville remains a pivotal entity in shaping the future of healthcare worldwide.
“Pharmsville Co. Ltd. trades at a P/E of 9.8 (undervalued) with modest ROE of 4.4%.”
Ask for details →Pharmsville Co. Ltd. (ticker: 318010) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 27 employees. Market cap is $28.2B.
The current price is ₩3,560 with a P/E ratio of 9.77x and P/B of 0.42x.
ROE is 4.41% and operating margin is -5.29%. Annual revenue is $12.7B.